GlaxoSmithKline plc (NYSE:GSK) declared a quarterly dividend on Thursday, November 1st, NASDAQ reports. Shareholders of record on Friday, November 16th will be given a dividend of 0.486 per share by the pharmaceutical company on Thursday, January 10th. This represents a $1.94 dividend on an annualized basis and a yield of 4.71%. The ex-dividend date is Thursday, November 15th. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.46.
GlaxoSmithKline has decreased its dividend payment by an average of 8.9% annually over the last three years. GlaxoSmithKline has a payout ratio of 66.0% indicating that its dividend is sufficiently covered by earnings. Analysts expect GlaxoSmithKline to earn $3.05 per share next year, which means the company should continue to be able to cover its $1.94 annual dividend with an expected future payout ratio of 63.6%.
NYSE GSK opened at $41.30 on Friday. GlaxoSmithKline has a 12 month low of $34.52 and a 12 month high of $42.36. The company has a debt-to-equity ratio of 6.66, a quick ratio of 0.63 and a current ratio of 0.95. The stock has a market capitalization of $101.21 billion, a price-to-earnings ratio of 14.34, a P/E/G ratio of 2.74 and a beta of 0.80.
GSK has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of GlaxoSmithKline from a “sell” rating to a “hold” rating in a research report on Tuesday, July 17th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Friday, July 20th. Bank of America set a $40.00 target price on shares of GlaxoSmithKline and gave the company a “hold” rating in a research report on Wednesday, July 25th. Shore Capital raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating in a research report on Friday, July 27th. Finally, Deutsche Bank reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, August 1st. Eleven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. GlaxoSmithKline presently has an average rating of “Hold” and a consensus target price of $41.57.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Further Reading: Market Capitalization – What it Means for Investors
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.